---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-157126"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:00:31.361961+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics receives Nasdaq delisting notice for equity shortfall; 45 days to submit plan

## Summary
- Nasdaq notified Alaunos on April 9, 2026, of non-compliance with minimum $2.5M stockholders' equity; 2025 10-K reported $2.153M.
- Company also fails alternative listing standards: market value of listed securities $35M or net income $500K last fiscal year.
- Must submit compliance plan by May 26, 2026; if accepted, Nasdaq may grant up to 180-day extension.
- If plan rejected or extension not achieved, Company may request hearing before Nasdaq hearings panel.
- Trading in TCRT common stock continues pending disclosure and compliance process.

## SEC filing metadata
- accession: 0001193125-26-157126
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312526157126/0001193125-26-157126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312526157126/tcrt-20260409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-157126
- JSON: https://secwatch.observer/filing/0001193125-26-157126.json
- Plain text: https://secwatch.observer/filing/0001193125-26-157126.txt

## Source-grounded claims
- claim_id: 7703361037369176634ec1a2fc3a7595971b9da0
  claim: Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, reported stockholders’ equity of $2,153,000. As of the date of the Notice
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312526157126/0001193125-26-157126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.